Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.43 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.43 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.43 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.43 |
| ▸ | IDO1 | P14902 | 3/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7087370 | 1.00 | BCHE (0.51) | BCHEACHEPSEN1PSEN2APH1B | |
| SCHEMBL4031189 | 1.00 | BCHE (0.51) | BCHEACHEPSEN1PSEN2APH1B | |
| SCHEMBL4179882 | 0.88 | BCHE (0.49) | BCHEACHEPSEN1PSEN2APH1B | |
| SCHEMBL4179879 | 0.88 | BCHE (0.49) | BCHEACHEPSEN1PSEN2APH1B | |
| SCHEMBL4179875 | 0.88 | BCHE (0.49) | BCHEACHEPSEN1PSEN2APH1B | |
| SCHEMBL23995897 | 0.75 | BCHE (0.62) | BCHEACHEPSEN1PSEN2APH1B | |
| SCHEMBL17925924 | 0.75 | BCHE (0.62) | BCHEACHEPSEN1PSEN2APH1B | |
| SCHEMBL4182846 | 0.73 | BCHE (0.59) | BCHEACHEPSEN1PSEN2APH1B | |
| SCHEMBL4175659 | 0.72 | BCHE (0.51) | BCHEACHEPSEN1PSEN2APH1B | |
| SCHEMBL21944472 | 0.71 | BCHE (0.53) | BCHEACHEPSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1272193-B1 | SYNERGISTIC COMBINATION THERAPY FOR TREATING CANCER | BRISTOL MYERS SQUIBB CO (US) | 2009-05-06 | — | — | EP | disclosed |
| EP-1372636-B1 | METRONOMIC DOSING OF TAXANES FOR INHIBITING TUMOR GROWTH | BRISTOL MYERS SQUIBB CO (US) | 2006-06-28 | — | — | EP | disclosed |
| EP-1623706-A2 | Metronomic dosing of taxanes for inhibiting tumor growth | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20050250844-A1 | Methods of treating cancer using C-4 carbonate taxanes | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-10 | — | — | US | disclosed |
| US-6916942-B2 | Process for the preparation of C-4 carbonate taxanes | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-12 | — | — | US | disclosed |
| US-20040225009-A1 | Process for the preparation of C-4 carbonate taxanes | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-11 | — | — | US | disclosed |
| EP-1251846-B1 | C-4 CARBONATE TAXANES | BRISTOL MYERS SQUIBB CO (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20040143004-A1 | Metronomic dosing of taxanes | CERAM TEC AG, INNOVATIVE CERAMIC ENGINEERING (DE) | 2004-07-22 | — | — | US | disclosed |
| US-6750246-B1 | NOVEL ORALLY ACTIVE PACLITAXEL DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-15 | — | — | US | disclosed |
| US-6537988-B2 | Imidazole-1h-1,4-benzodiazepine derivatives along with antiproliferative cytotoxic and cytostatic agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-03-25 | — | — | US | disclosed |
| EP-1251846-A4 | C-4 CARBONATE TAXANES | BRISTOL MYERS SQUIBB CO (US) | 2003-03-12 | — | — | EP | disclosed |
| EP-1272193-A2 | SYNERGISTIC METHODS AND COMPOSITIONS FOR TREATING CANCER | Bristol-Myers Squibb Company (US) | 2003-01-08 | — | — | EP | disclosed |
| EP-1251846-A1 | C-4 CARBONATE TAXANES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-30 | — | — | EP | disclosed |
| WO-2001072721-A2 | SYNERGISTIC METHODS AND COMPOSITIONS FOR TREATING CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-10-04 | — | — | WO | disclosed |
| WO-2001056565-A1 | C-4 CARBONATE TAXANES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040143004-A1 | Metronomic dosing of taxanes | MTDH, MCL1, CCNA1 | BCHE 4673/4885ACHE 4803/4885PSEN1 3369/4885 |
| US-20050250844-A1 | Methods of treating cancer using C-4 carbonate taxanes | CA4, CA14, CA13 | BCHE 2544/4885ACHE 4733/4885PSEN1 4320/4885 |
| US-20040225009-A1 | Process for the preparation of C-4 carbonate taxanes | CA4, CA14, CDK4 | BCHE 4155/4885ACHE 4863/4885PSEN1 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.